How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

8,360 results for

Skin Conditions in Diabetes Mellitus

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Polyneuropathy in Diabetes Mellitus Type 2

Polyneuropathy in Diabetes Mellitus Type 2 Polyneuropathy in Diabetes Mellitus Type 2 - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Polyneuropathy in Diabetes Mellitus Type 2 The safety and scientific (...) Description Go to Brief Summary: This is a population-based study of type 2 diabetes patients with and without neuropathy recruited from the Danish National Type 2 Diabetes cohort (DD2). Perspective: The study will identify risk factors for developing diabetic polyneuropathy and painful diabetic polyneuropathy and provide information on the underlying mechanisms, which will hopefully contribute to significant improvements in the treatment and prevention of diabetic polyneuropathy in future. Condition

2016 Clinical Trials

102. Environmental Effects Type 1 Diabetes Mellitus

Environmental Effects Type 1 Diabetes Mellitus Environmental Effects Type 1 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Environmental Effects Type 1 Diabetes Mellitus The safety (...) : Type 1 Diabetes mellitus (T1D) is characterized by βcell destruction and a long life requirement of exogenous insulin. The bolus basal insulin regimen is a widely accepted therapy concept to treat hyperglycaemia in patients with T1D. This concept requires a very good knowledge of the individuals prandial and basal insulin requirements. However, insulin requirement depends on insulin absorption from the injection site and the individual's insulin sensitivity which relies on a number of effects

2016 Clinical Trials

103. Transcutaneous Electrical Nerve Stimulator to Improve Blood Glucose Control in Patients With Type 2 Diabetes Mellitus

control, as measured by change of glycated hemoglobin (HbA1c). The second study objectives are to demonstrate that DW1330 is associated with the mechanism of glycemic control and inflammation pathways. The study is also aimed to investigate the safety of DW1330. Condition or disease Intervention/treatment Phase Type 2 Diabetes Mellitus Device: Transcutaneous Electrical Nerve Stimulator (DW1330) Device: Sham DW1330 device Not Applicable Detailed Description: This is a multi-center, prospective, double (...) Transcutaneous Electrical Nerve Stimulator to Improve Blood Glucose Control in Patients With Type 2 Diabetes Mellitus Transcutaneous Electrical Nerve Stimulator to Improve Blood Glucose Control in Patients With Type 2 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number

2016 Clinical Trials

104. Tissue-Muscle Perfusion Scintigraphy of the Lower Limbs in a Patient with Type 2 Diabetes Mellitus and Peripheral Arterial Disease (Full text)

in basal conditions ("rest" study) and exercise conditions ("stress" study). Emphasis is given on perfusion reserve (PR) as an important indicator of preservation of microcirculation and its local autoregulatory mechanisms in PAD. We present a case of a 71-year-old male diabetic patient with skin ulcers of the right foot and an ankle-brachial index >1.2 (0.9-1.1). Dynamic phase TMPS of the lower limbs showed decreased and late arterial vascularization of the right calf (RC) with lower percentage (...) Tissue-Muscle Perfusion Scintigraphy of the Lower Limbs in a Patient with Type 2 Diabetes Mellitus and Peripheral Arterial Disease The estimation of tissue perfusion as a hemodynamic consequence of peripheral arterial disease (PAD) in diabetic patients is of great importance in the management of these patients.We present a noninvasive, functional method of 99mTc-MIBI (methoxy-isobutyl-isonitrile) tissue-muscle perfusion scintigraphy (TMPS) of the lower limbs, which assesses tissue perfusion

2016 Molecular Imaging and Radionuclide Therapy PubMed

105. Prospective, Comparitive, Randomized Study of Allograft Versus Skin Substitute in Non-healing Diabetic Foot Ulcers

engineered skin substitute, when used to treat diabetic foot ulcers (DFUs). Condition or disease Intervention/treatment Phase Diabetic Foot Ulcer Procedure: Tissue Engineered Skin Substitute Device: Offloading Procedure: Amnionic Membrane Graft Not Applicable Detailed Description: Diabetes affects at least 9% of the population, or approximately 29 million people in the United States. Lower extremity ulcers are a serious complication for people with diabetes. Diabetic foot-related problems are the most (...) Prospective, Comparitive, Randomized Study of Allograft Versus Skin Substitute in Non-healing Diabetic Foot Ulcers Prospective, Comparitive, Randomized Study of Allograft Versus Skin Substitute in Non-healing Diabetic Foot Ulcers - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number

2016 Clinical Trials

106. ExpressGraft-C9T1 Skin Tissue as a Treatment of Diabetic Foot Ulcers

. Targeted enrollment for this study is up to 6 subjects with a confirmed diagnosis of diabetes and who have foot ulcers. Subjects will each receive a single application of ExpressGraft-C9T1 skin tissue on a single identified study DFU following a 10-14 day run-in period. Any subjects requiring additional treatment will receive protocol-defined dressings through Study Treatment Week 12 as necessary. Enrollment will occur with a minimum of one week between each subject. Condition or disease Intervention (...) Ulcer Skin Diseases Diabetes Complications Diabetes Mellitus Endocrine System Diseases Diabetic Neuropathies Foot Diseases

2016 Clinical Trials

107. Skin fluorescence as a clinical tool for non-invasive assessment of advanced glycation and long-term complications of diabetes (Full text)

to micro- and macrovascular complications in both type 1 and type 2 diabetes mellitus and is associated with mortality in type 2 diabetes. The relation between skin fluorescence and cardiovascular disease also extends to other conditions with increased tissue AGE levels, such as renal failure. Besides cardiovascular complications, skin fluorescence has been associated, more recently, with other prevalent conditions in diabetes, such as brain atrophy and depression. Furthermore, skin fluorescence (...) Skin fluorescence as a clinical tool for non-invasive assessment of advanced glycation and long-term complications of diabetes Glycation is important in the development of complications of diabetes mellitus and may have a central role in the well-described glycaemic memory effect in developing these complications. Skin fluorescence has emerged over the last decade as a non-invasive method for assessing accumulation of advanced glycation endproducts. Skin fluorescence is independently related

2016 Glycoconjugate journal PubMed

108. Effect of a Basic Skin Care Product on the Structural Strength of the Skin

, Body Mass Index between 20 and 28 kg/m2, Non-smoker of at least one year, Absence of skin diseases or scars in the skin area of interest, Absence of tattoos in the skin area of interest, Able to give written informed consent, Willing and able to fulfill the study requirements Exclusion Criteria: Known or suspected defect of healing, Diabetes mellitus Any acute or chronic pathology that may interfere with the trial conduct, from investigator point of view, Acute or chronic wounds in the skin area (...) . Jan Kottner, Charite University, Berlin, Germany Study Details Study Description Go to Brief Summary: The main aim of this study is to investigate in a suction blister model, whether the use of a basic skin care formulation increases the mechanical integrity/adhesion of the dermo-epidermal junction. Condition or disease Intervention/treatment Phase Healthy Skin Other: Treatment with petrolatum Not Applicable Detailed Description: The process of aging involves numerous structural and functional

2018 Clinical Trials

109. Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes Mellitus

Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes Mellitus Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached (...) the maximum number of saved studies (100). Please remove one or more studies before adding more. Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes Mellitus The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01821846 Recruitment Status

2013 Clinical Trials

110. Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Full-Thickness Skin Defects in Adults and Children

procedures Signed Informed consent Exclusion Criteria: Patients tested positive for HBV, HCV, syphilis or HIV Patients with known underlying or concomitant medical conditions that may interfere with normal wound healing (e.g. systemic skin and connective tissue diseases, any kind of congenital defect of metabolism including insulin-dependent diabetes mellitus, Cushing syndrome or disease, scurvy, chronic hypothyroidism, congenital or acquired immunosuppressive condition, chronic renal failure, or chronic (...) to meshed STSG in adults and children with full-thickness Skin defects. Condition or disease Intervention/treatment Phase Skin Wound Biological: EHSG-KF Biological: STSG Phase 2 Detailed Description: This multicentre phase II clinical trial will target adults and children with fullt-thickness skin defects to elucidate the benefit of a tissue-engineered autologous skin substitute. Particular emphasis, apart from safety, will be placed on efficacy, e.g. scar quality, in comparison to meshed STSG. Study

2017 Clinical Trials

111. Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada : Diabetes in the elderly

of diabetes care, particularly for older adults who may require additional education and support in light of other chronic conditions and polypharmacy . Recently, a population-based cohort study of older adults (≥65 years of age) living in Ontario found that attendance at a diabetes education program was associated with better quality of care, and better participation relating to education utilization and retinopathy screening . A review of diabetes self-management programs for older adults ≥65 years (...) and insulin sensitivity in these people, although this is controversial . Older women with diabetes have a greater decline in walking speed when compared to a control group without diabetes . In the older population with diabetes, higher levels of physical activity are associated with greater survival . Physical training programs can be successfully implemented in older people with diabetes, although comorbid conditions may prevent aerobic physical training in many patients, and increased activity levels

2013 CPG Infobase

112. Comorbid conditions in lichen planopilaris: A retrospective data analysis of 334 patients (Full text)

(6.3% vs. 0%; p = .023), hypothyroidism (24.3% vs. 12.8%; p = .028), and hirsutism (11.4% vs. 1.3%; p = .006). Negatively associated conditions were allergic rhinitis (15% vs. 24.4%; p = .046), diabetes mellitus type II (11.7% vs. 21.8%; p = .019), hyperlipidemia (38.6% vs. 52.6%; p = .024), vitamin D deficiency (50% vs. 65.4%; p = .014), depression (15.6% vs. 28.9%; p = .018), and sleep problems (7.5% vs. 29.5%; p < .001).Our study further emphasizes that dermatologists should screen patients (...) Comorbid conditions in lichen planopilaris: A retrospective data analysis of 334 patients Lichen planopilaris (LPP) is a rare, cicatricial, lymphocyte-mediated alopecia that is thought to have an autoimmune pathogenesis and possibly related to other autoimmune diseases. However, data are limited and studies that examine comorbid conditions are lacking.We sought to determine the prevalence of systemic comorbid conditions, nutritional deficiencies, psychological problems, and skin cancers

2018 International journal of women's dermatology PubMed

113. Treatment of Diabetes in Older Adults

is hospitalized. Overall diabetes management. For selected patients, the endocrinologist or diabetes care specialist and the diabetes care team are primarily responsible for diabetes care and collaborate with providers who manage the patient’s other health problems and comorbidities. This situation may occur by default if the patient has no primary care provider or if the patient is already under the care of the endocrinologist or diabetes care specialist for long-standing T1D or other endocrine conditions (...) Cognition Bone mineral density Neuropathy Fall risk AAA ultrasound Medical nutrition therapy Weight (kg)/height (m) 2 = BMI Diabetes screening (for nondiabetic persons) Diabetes management Blood pressure Diabetes self-management training Tobacco use Alcohol use Medication review Cancer screening Hearing Comorbid conditions Visual acuity Frailty/physical performance General Health Assessment General Health Tests Diabetes-Specific Health Functional status (ADLs/IADLs ) ECG Retinopathy Depression Lipid

2019 The Endocrine Society

114. Skin Blood Flow in Patients With Type 1 Diabetes Mellitus Compared to Normal Controls

bone biopsies. Condition or disease Type 1 Diabetes, Bone Study Design Go to Layout table for study information Study Type : Observational Actual Enrollment : 78 participants Observational Model: Case Control Time Perspective: Cross-Sectional Official Title: Skin Blood Flow in Patients With Type 1 Diabetes Mellitus Compared to Normal Controls Study Start Date : May 2012 Actual Primary Completion Date : August 2013 Actual Study Completion Date : August 2013 Resource links provided by the National (...) Skin Blood Flow in Patients With Type 1 Diabetes Mellitus Compared to Normal Controls Skin Blood Flow in Patients With Type 1 Diabetes Mellitus Compared to Normal Controls - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before

2012 Clinical Trials

115. Management of Diabetic Foot

Practice Guidelines published in 2015 (available at http://www.moh. gov.my/penerbitan/mymahtas/CPG_MANUAL_MAHTAS.pdf). vManagement of Diabetic Foot (Second Edition) OBJECTIVES The objectives of the CPG are to provide evidence-based recommendations on the management of diabetic foot in the following aspects: a. assessment b. referral c. prevention d. treatment CLINICAL QUESTIONS Refer to Appendix 2. TARGET POPULATION Inclusion Criteria All patients with diabetes mellitus who are at risk or have (...) infection • critical limb ischaemia • gangrene • suspicion of an acute charcot neuroarthropathy or an unexplained hot, red, swollen foot with or without pain All patients with diabetes Foot assessment: • skin • neurological • vascular • musculoskeletal Active foot problem? Refer Algorithm B Previous history of ulceration, amputation or on renal replacement therapy? High risk* Early referral to Foot Protection Services NO YES YES NO Deformity/ neuropathy/ non-critical limb ischaemia Moderate risk* Low

2018 Ministry of Health, Malaysia

116. Flash Glucose Monitoring System for Diabetes

, mealtime insulin. 3 Some people with hard-to-control type 1 diabetes may opt for continuous glucose monitoring with devices that continuously measure glucose levels using a sensor implanted under the skin. 3 Other people may opt for continuous monitoring because they find the number of finger sticks required for self-monitoring to be painful and inconvenient. A new approach to glucose monitoring, called flash glucose monitoring, is becoming available and may offer people with type 1 and type 2 diabetes (...) interval; Dexcom = Dexcom G4 Platinum continuous glucose monitoring system; FSL = FreeStyle Libre system; MARD = mean absolute relative difference; MD-CGM = intravascular microdialysis continuous glucose monitoring; Medtronic = Medtronic MiniMed 640G insulin pump; pts = patients; SMBG = self-monitoring of blood glucose; T1DM/T2DM = type 1 and type 2 diabetes mellitus; vs. = versus; YSI = Yellow Springs Instrument Company. a Error grid analysis pairs glucose samples in five zones (A, B, C, D, and E). 32

2018 CADTH - Issues in Emerging Health Technologies

117. MKSAP: 40-year-old man with a new skin rash of 10 days’ duration

MKSAP: 40-year-old man with a new skin rash of 10 days’ duration Eruptive xanthomas in patients with diabetes mellitus MKSAP: 40-year-old man with a new skin rash of 10 days’ duration | | March 9, 2019 2 Shares Test your medicine knowledge with the , in partnership with the . A 40-year-old man is evaluated for a new skin rash of 10 days’ duration. The rash appeared abruptly and is not tender or pruritic. The patient has poorly controlled type 2 diabetes mellitus. His current medications include (...) a diagnosis of diabetes mellitus. Eruptive xanthomas have also been reported as a complication of hypertriglyceridemia-induced pancreatitis. Tuberous xanthomas are associated with markedly elevated low-density lipoprotein levels (familial hypercholesterolemia) and elevated intermediate-density lipoprotein and triglyceride levels (familial dysbetalipoproteinemia). Tuberous xanthomas present as yellow to red papules or nodules up to 3 cm in size located over joints and extensor surfaces of the elbows

2019 KevinMD blog

118. Factors associated with readmission and mortality in adult patients with skin and soft tissue infections. (PubMed)

), ischemic heart disease (P = 0.01), chronic liver disease (P = 0.001), and diabetes mellitus (DM) (P = 0.006). The number of patients who died as a result of an infection was 34 (2.2%) and, in these patients, the most common diagnosis was also cellulitis (79.4%), which in 52.9% (P = 0.001) was community acquired. DM (P = 0.01), heart failure (P = 0.001), and chronic liver disease (P = 0.003) were the most frequent comorbidities. This group presented more complications (P < 0.005) such as endocarditis (P (...) Factors associated with readmission and mortality in adult patients with skin and soft tissue infections. Skin and soft tissue infections (SSTIs) are a common cause of consultation, and complicated cases require hospitalization. We describe factors that are related to readmission and/or mortality of hospitalized patients diagnosed with SSTIs.Retrospective review of hospital-admitted patients with a diagnosis of cellulitis, abscess, hidradenitis, fasciitis, and Fournier's gangrene. Cases from

2019 International Journal of Dermatology

119. Skin Autofluorescence (AF) Decision Tree in Detecting Impaired Glucose Tolerance (IGT) or Diabetes Mellitus (DM)

), glycated haemoglobin (HbA1c), and to two short questionnaires (Finnish Findrisk, and Cambridge score). Study design: Skin AF, HbA1c and an oGTT (including an FPG) will be simultaneously performed in at least 120 persons with the characteristics described in the following paragraph. A Findrisk and Cambridge questionnaire will also be collected. Condition or disease Diabetes Mellitus Impaired Glucose Tolerance Study Design Go to Layout table for study information Study Type : Observational Actual (...) Skin Autofluorescence (AF) Decision Tree in Detecting Impaired Glucose Tolerance (IGT) or Diabetes Mellitus (DM) Skin Autofluorescence (AF) Decision Tree in Detecting Impaired Glucose Tolerance (IGT) or Diabetes Mellitus (DM) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2011 Clinical Trials

120. Islet Cell Replacement Therapy for Insulin-Dependent Diabetes

that may help protect them from the immune system. 3,5 The PEC-Direct Product The PEC-Direct product contains PEC-01 cells; it is surgically implanted under the skin during an outpatient procedure. 9 Due to the auto-immune nature of type 1 diabetes, as well as the fact that these cells are allogeneic (genetically similar but not identical), patients are expected to require immunosuppression for the rest of their lives. 3,4 The risks of lifelong immunosuppression include an increased risk of infections (...) PEC-Encap product uses the same PEC-01 cells as the PEC-Direct product, and it is also implanted under the skin during an outpatient procedure. 3,10 However, the PEC-Encap product takes the PEC-Direct technology one step further by enclosing the cells in a semi-permeable encapsulation device. The device — called the Encaptra drug delivery system — is hypothesized to prevent the need for immunosuppression. 3,7,9-11 The PEC-Encap product is intended for all people living with type 1 diabetes as well

2017 CADTH - Issues in Emerging Health Technologies

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>